Drug Discovery@nature.com 21 March 2014

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS 21 March 2014 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement nature.com webcasts Macmillan Science Communication presents a custom webcast: Going low: use of peptide:MHCII tetramer-based cell enrichment to study the CD4+ T cell response.   Monday April 7th at 9am PDT / 12pm EDT / 5pm BST / 6pm CEST   Register for the free webcast followed by a live Q & A session    Sponsored by:      News Top NIH rethinks psychiatry trials doi:10.1038/507288a Mental-health division will no longer fund research aiming to relieve symptoms of psychiatric disorders without probing underlying causes. Full Text First recombinant Factor XIII approved doi:10.1038/nbt0314-210a Despite higher costs, catridecacog is expected to supersede plasma-derived counterparts, which carry the risk of transmitting infectious diseases, for treatment of congenital Factor XIII A-subunit deficiency. Full Text Roche bets on alpha-synuclein for Parkinson's doi:10.1038/nbt0314-212a Roche's recent deal with Prothena to develop and commercialize a monoclonal antibody against alpha-synuclein signals mounting interest in this target. Full Text Competition aims to revive languishing breast cancer inventions doi:10.1038/nm0314-223 The US National Cancer Institute has launched a competition to encourage entrepreneurs to take on the development of the many therapies and devices in the institute’s portfolio for women with breast cancer. Full Text Analysis Top Killer targets in metastasis doi:10.1038/scibx.2014.274 An international team has found a new pathway in natural killer (NK) cells that leads to the rejection of metastatic tumours. Full Text Systemic lupus erythematosus and lupus nephritis doi:10.1038/nrd4220 The likely market impact of the late-stage pipeline for systemic lupus erythematosus (SLE) and lupus nephritis (LN), which contains biologics and small-molecule drugs for a broad range of targets. Full Text Research Highlights Top Inflammatory disorders: Monocytes derailed by microparticles doi:10.1038/nrd4263 Microparticles that target inflammatory monocytes can dampen inflammation and alleviate symptoms in several mouse models of immune-mediated disease. Full Text Vascular disease: A new way to starve vascular endothelial cells doi:10.1038/nrd4264 Partial inhibition of glycolysis with a small-molecule drug could ameliorate pathological angiogenesis, which occurs in various diseases including cancer. Full Text Neurological disorders: Presynaptic glycine receptors become a startling target doi:10.1038/nrd4265 A cannabinoid derivative that seems to target presynaptic glycine receptors could have therapeutic potential in startle disease. Full Text Research & Reviews Top REV-ERB and ROR nuclear receptors as drug targets doi:10.1038/nrd4100 A Review on the development of ligands to target two classes of nuclear receptors — the REV-ERBs and RORs — and their possible use in treating disorders related to metabolism, immune function and the circadian rhythm. Full Text Drugging the p53 pathway: understanding the route to clinical efficacy doi:10.1038/nrd4236 In this Review, Lane and colleagues provide an overview of the different therapeutic approaches to targeting the p53 pathway in cancer and discuss the state of development of p53 pathway modulators. Full Text Opinion: Targeting tumour-supportive cellular machineries in anticancer drug development doi:10.1038/nrd4201 The advantages and limitations of agents that target tumour-supportive cellular machineries — such as the proteasome, heat shock protein complexes and proteins involved in chromatin modifications — which are emerging as a new wave of anticancer drugs. Full Text Progress: The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells doi:10.1038/nrmicro3200 Veronique Dartois describes new methods to quantify and image anti-tuberculosis drug distribution in infected lung tissue and mycobacterial cells, and explores how this technology could be used to design optimized multidrug regimens. Full Text Drug Discovery JOBS of the week Postdoc in Cancer Drug Delivery University of Tartu PhD Position on Bionanotechnology for Sensing, Drug Delivery and Cell Culture Universitat Rovira i Virgili-DEEEA 4-Year Fully Funded Studentship in "Computation of Allosteric Interactions in Biomolecular Drug Targets’’ University of Edinburgh Tenure-Track and Postdoctoral Scientists in Molecular Profiling Research Center for Drug Discovery, AIST National Institute Advanced Industrial Science and Technology (AIST) Staff Scientist - Aerosol Drug Delivery Wyss Institute for Biologically Inspired Engineering More Science jobs from Drug Discovery EVENT 15th International Conference on Alzheimer’s Drug Discovery 08.09.14 New Jersey, USA More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.